Pentixapharm Acquires Target Discovery Business of Glycotope
Pentixapharm AG, a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals against…
Pentixapharm AG, a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals against…
Pentixapharm AG, a radiopharmaceutical development company wholly owned by Eckert & Ziegler SE, today announced that it…
Die Pentixapharm AG, ein Unternehmen, das Radiopharmazeutika entwickelt und sich zu 100% im Besitz der Eckert & Ziegler…
Eckert & Ziegler BEBIG GmbH, subsidiary of Eckert & Ziegler SE with focus on brachytherapy solutions for the treatment o…
Eckert & Ziegler (ISIN DE0005659700, SDAX) and Nucleus Radiopharma (Nucleus) signed extensive supply agreements for maj…
Eckert & Ziegler (ISIN DE0005659700, SDAX) and Full-Life Technologies (Full-Life), a clinical stage, fully integrated gl…
Eckert & Ziegler (ISIN DE0005659700, SDAX) and ARTBIO, Inc. (ARTBIO), a clinical-stage biotechnology company specializin…
Pentixapharm AG, a developer of innovative radiopharmaceuticals owned by Eckert & Ziegler Strahlen- und Medizintechnik A…
Eckert & Ziegler (ISIN DE0005659700, SDAX) and PharmaLogic Holdings Corp. (“PharmaLogic”) have signed a reservation agre…
Eckert & Ziegler AG (ISIN DE0005659700, SDAX) today signed an agreement with POINT Biopharma Global Inc. ("POINT", NASDA…